Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327101 | 0.90 | TSHR (0.52) | TSHRSRD5A2KMOKDM4EPOLB | |
| SCHEMBL7964744 | 0.84 | TSHR (0.48) | TSHRSRD5A2KMOKDM4EPOLB | |
| SCHEMBL7975027 | 0.84 | TSHR (0.48) | TSHRSRD5A2KMOKDM4EPOLB | |
| SCHEMBL727064 | 0.81 | TSHR (0.59) | TSHRSRD5A2KMOHSD11B1 | |
| SCHEMBL7974984 | 0.81 | TSHR (0.46) | TSHRSRD5A2KMOKDM4EPOLB | |
| SCHEMBL7977632 | 0.80 | HPGD (0.50) | TSHRKDM4EPOLBHPGDHTT | |
| SCHEMBL10193619 | 0.79 | ALOX15 (0.50) | TSHRSRD5A2KDM4EPOLBHPGD | |
| SCHEMBL7964353 | 0.79 | TSHR (0.47) | TSHRSRD5A2KMOKDM4EPOLB | |
| SCHEMBL12327098 | 0.78 | TSHR (0.44) | TSHRSRD5A2KMOPOLBHPGD | |
| SCHEMBL7976173 | 0.77 | KMT2A (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350184-B2 | Derivatives used in the treatment of muscle atrophy | METABRAIN RESEARCH (FR) | 2019-07-16 | — | — | US | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010011302-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | TSHR 4092/4885SRD5A2 1168/4885KMO 1/4885 |
| US-10350184-B2 | Derivatives used in the treatment of muscle atrophy | PYGM, GYS1, MUSK | TSHR 750/4885SRD5A2 84/4885KMO 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.